Researchers have identified three functional subtypes of these cells, which correspond to patients’ treatment response.
Alcohol-related liver disease is currently the most common reason for liver transplantation in the United States. In recent years, high-risk drinking of alcohol—defined as exceeding daily drinking limits (more than 4 or 5 standard drinks for women and men, respectively) at least weekly for a whole year—has increased in nearly all sociodemographic groups, especially in women.
A new analysis by researchers at Massachusetts General Hospital, Harvard Medical School and Georgia Tech indicates that cases of alcohol-related liver disease will rise dramatically in the coming years without drastic steps to reduce high-risk drinking rates.
To project the impact of alcohol-related liver disease over the next two decades, the team developed a model of drinking patterns and alcohol-related liver disease in individuals born in 1900 to 2012 in the United States, with projections up to 2040. The model relied on data from multiple sources: the National Epidemiologic Survey on Alcohol and Related Conditions, the National Institute of Alcohol Abuse and Alcoholism, the US National Death Index, the National Vital Statistics System and numerous published studies. The model was validated in that it closely reproduced the trends in deaths due to alcohol-related liver disease that were observed from 2005 to 2018.
Jagpreet Chhatwal, PhD
Our study underscores the need to bring alcohol-related disease to the forefront of policy discussions and identify effective policies to reduce high-risk drinking in the U.S.
Senior scientist, MGH Institute for Technology Assessment
In the Lancet Public Health analysis, future trends in alcohol-related liver disease were modelled under three potential scenarios based on the level of interventions to address high-risk drinking:
- Without any changes in trends in alcohol consumption (status quo), more than 1 million people could die from alcohol-related liver disease by 2040, of whom 35% are projected to be younger than 55 years
- Reducing high-risk drinking rates to 2001 levels could prevent 35,000 deaths during the same time period
- In contrast, decreasing the high-risk drinking rate by 3.5% per year—similar to the decrease in the rate of tobacco consumption observed after implementation of policies and social interventions in the 1960s to reduce smoking in the U.S.—could prevent 299,000 deaths compared with the status quo scenario (a 30% decrease)
The analysis also projected that in comparison with status quo, decreasing the high-risk drinking rates by 3.5% per year could prevent alcohol-related liver cancer and decompensated cirrhosis (a form of advanced liver disease) by 30% from 2019 to 2040.
“Our study underscores the need to bring alcohol-related disease to the forefront of policy discussions and identify effective policies to reduce high-risk drinking in the U.S.,” said senior author Jagpreet Chhatwal, PhD, a senior scientist at the MGH Institute for Technology Assessment and an assistant professor at Harvard Medical School.
Lead author Jovan Julien, MS, a PhD student at Georgia Tech, noted that the impact of high-risk drinking takes years to observe. “Our model highlights the long-term risk, especially for younger generations whose drinking continues to outpace older generations,” he said. “Given the practical infeasibility of clinical trials to study long-term effects of increased alcohol consumption, data-driven modeling studies such as ours are valuable for understanding the implications of high-risk drinking and making informed policy decisions,” added co-author Turgay Ayer, PhD, MSc, an associate professor at Georgia Tech.
Paper Cited: Julien J, Ayer T, Bethea ED, Tapper EB, Chhatwal J (2020) Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study Lancet Public Health
Funding Information: American Cancer Society Research Scholar and the Robert Wood Johnson Health Policy Research Fellowship
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2019, Mass General was named #2 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Oct | 20 | 2021
Immune checkpoint inhibitors caused changes to immune cells in the cerebrospinal fluid of treated patients and generated promising results in a phase II clinical trial.
- Press Release
- Oct | 19 | 2021
In pregnant women with COVID-19, sex of fetus may influence maternal and placental immune response and neonatal immune protection
The placentas of male and female fetuses respond very differently when a mother is infected with SARS-CoV-2 during pregnancy. Male placentas have significantly increased immune activation, and males receive significantly fewer anti-COVID antibodies from their mothers.
- Press Release
- Oct | 15 | 2021
‘Superhuman, but never enough’: Essay details inequities experienced by Black women physicians in the United States
A long history of discrimination against Black women physicians persists and contributes to their underrepresentation in medicine, argue physician-scientist Fatima Cody Stanford and her coauthors.
- Press Release
- Oct | 14 | 2021
Increasing moderate-to-vigorous physical activity by 17 minutes per day, adding 54 minutes of walking per day, or reducing 249 minutes of sedentary time per day corresponded to a 5% higher peak oxygen uptake during exercise.
- Oct | 11 | 2021
New research published in PNAS that was led by investigators at Massachusetts General Hospital (MGH) and the University of Geneva (UNIGE) provides insights on why some types of colorectal cancer don’t respond to immune checkpoint inhibitors and offers a strategy to overcome their resistance.